Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
4.640
+0.030 (0.65%)
At close: Nov 14, 2025, 4:00 PM EST
4.600
-0.040 (-0.86%)
After-hours: Nov 14, 2025, 6:31 PM EST
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
38
Market Cap
254.73M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | 125.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CADL News
- 3 days ago - Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 12 days ago - Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors - GlobeNewsWire
- 13 days ago - Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc. - GlobeNewsWire
- 4 weeks ago - Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer - PRNewsWire
- 4 weeks ago - Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine - GlobeNewsWire
- 4 weeks ago - Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now - Seeking Alpha